HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

▼

Showing posts with label BMS-650032 and BMS-790052. Show all posts

Showing posts with label BMS-650032 and BMS-790052. Show all posts

Sunday, May 13, 2012

EASL Video Highlights-BMS-790052/BMS-650032 Also PSI-7977 PROTON and ELECTRON

Happy Mothers Day! A special heartfelt Mothers day goes out to all the ladies who are burdened with the challenge of living with HCV. Ta...

Tuesday, November 8, 2011

AASLD-All-Oral Regimen of daclatasvir (BMS-790052) and (BMS-650032) 90% SVR at 12wks

All-Oral Treatment Regimen of Bristol-Myers Squibb's Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response ...

Friday, September 30, 2011

AASLD-New Data On BMS-790052 and BMS-650032 to be presented by Bristol-Myers Squibb

September 30, 2011 11:19 AM EDT Bristol-Myers Squibb to Present New Data Demonstrating Company’s Leadership in Liver Disease at The Liver ...

Tuesday, August 16, 2011

Hepatitis Digest;HCV abstract-BMS-790052, Liver Cancer,Vitamin D and Diabetes

HCV abstracts Aug 2011; Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with h...

Saturday, April 2, 2011

Bristol-Myers Interferon-Free Combo And 4-Drug Combo Impressive "BMS-650032/BMS-790052" Plus SOC

Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment Is this treatment approach the next HCV ther...

View web version

Powered by Blogger.